Where I see patients (3)
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.
Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
British journal of haematology
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
To compare the rate of MRD >=0.01% at end of induction between experimental arm and control arm
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
DFS is defined as the time from the date of tisagenlecleucel infusion to the date of the first documented morphological relapse, occurrence of secondary malignancy or death due to any cause.
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Ly...
Will be reported as number and percentage of patients meeting CR/CRi criteria at the end of 8 weeks of therapy
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Pati...
Will test the null hypothesis (HR=1) for PFS using stratified log-rank test with a one-sided alpha of 0.021. The analysis will be based on modified intent-to-treat and will include all eligible patients as randomized regardless of...
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
to assess overall response rate following chemoimmunotherapy induction therapy
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemo...
The incidence of dose limiting toxicity (DLT) will be measured at different dose levels.
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed...
MTD defined as the highest dose level at which less than 33% of 6 patients experience a dose limiting toxicity (DLT), will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4...
Learning never stops